|Initial phase II clinical study of APC201 in Australia
|Andros Pharmaceuticals passed TFDA follow-up inspection of PICS/GMP
|APC101 for the indication above the neck has sent to TFDA for Phase II clinical trials application
|Finished phase I clinical study of APC201 in Australia
|The total paid-in capital was increased to 448 million NTD After the eighth round of cash capital increase
|Received Australia Bellberry Human Research Ethics Committee and TGA approval of Phase I/II clinical trials of APC201
|The company has been listed on the Emerging Stock Board (ESB) of the Taipei Exchange on January 12, 2023
|The company has been approved for public issuance of shares and the stock symbol is「6917」
|Complete the seventh round financing July 2022. The capital increased to NTD 348M
|APC201 sent to Australia and Taiwan for planned to enter Phase I/II clinical trials
|Complete the sixth round financing in February 2022. The capital increased to NTD 284 M
|LALP cream officially entered the hospital system for sales
|Andros Pharmaceuticals passed TFDA follow-up inspection of GMP.
|" Development of Topical New Dosage Form of Local Anesthetic Complex" project has received R&D subsidies from the Ministry of Ec
|Signed a licensing cooperation contract of LALP cream with Hong Kong Pharmaceuticals to develop the local anesthetics market in
|APC101 completed the phase IIa clinical trial report in Australia.
|President Ae-June Wang received the Excellence in Management Award at the 7th Woman Elite Entrepreneurs Competition.
|Andros Pharmaceuticals received Taiwan FDA licenses for 2% and 5% iMinos Solution (site change)
|Andros Pharmaceuticals passed TFDA audit inspection of GMP and GDP.
|Andros Pharmaceuticals received Taiwan FDA license for LALP Cream (site change)
|Andros Pharmaceuticals received innovative product award from Hsinchu Science Park on December 2016
|Andros Pharmaceuticals won the excellent execution award of SBIR program on October 2016
|The Commercial Times reported Andros won the award of SBIR program
|Andros Pharmaceuticals got the certificate of PIC/S GMP for adding liquid dosage form.
|Andros Pharmaceuticals got the certificate of PIC/S GMP.
|Complete the fifth round financing in March 2015. The capital increased to NTD 243M.
|Complete the forth round financing in February 2015. The capital increased to NTD 213M.
|"The preclinical study of the topical anesthetic new dosage form" project has received the SBIR grant from MOEA.
|"The subsequent project of topical delivery system development" received R&D subsidy from Taipei city government.
|The Commercial Times reported the recent development of Andros Pharmaceuticals and praised our performance.
|Andros Pharmaceuticals is recognized by Ministry of Economic Affairs as a “Biotech and New Pharmaceuticals Company”.
|Complete the third round financing in July 2013. The capital increased to NTD 150M.
|The newest job opportunities are available now
|"The development of topical delivery system" project received research and development subsidy from Taipei city government.
|The Commercial Times reported Andros Pharmaceuticals entered Hsinchu Biomedical Science Park.
|Andros Pharmaceuticals has relocated to Hsinchu Biomedical Science Park on 2nd Jan, 2013.
|Complete the second round of financing in October 2012. The capital increased to NTD 100M.
|Received NTD 12M of SBIR grant from MOEA for the development of “topical anesthetic new dosage form” project.
|Opening of the Hsinchu biomedical science park research building attended by President Ma Ying-Jeou.
|Approved by Hsinchu biomedical science park for relocation in late-2012.